Table 2.
Filled LLT prescriptions in the overall cohort and hierarchical subgroups
| Recent ACS (n = 23 040, 2%) | Other CHD (n = 419 010, 40%) | Ischemic Stroke (n = 37 309, 4%) | PAD (n = 123 960, 12%) | Only DM (n = 452 613, 43%) | Total Cohort (N = 1 055 932) | |
|---|---|---|---|---|---|---|
| High‐intensity statin, % 1 | 27.0 | 16.5 | 9.4 | 6.4 | 7.4 | 11.4 |
| Monotherapy | 96.2 | 90.4 | 96.7 | 93.8 | 94.5 | 92.2 |
| Plus ezetimibe | 2.6 | 6.7 | 2.3 | 4.1 | 3.5 | 5.3 |
| Plus other nonstatin LLT | 1.2 | 3.0 | 1.0 | 2.1 | 2.0 | 2.5 |
| Moderate‐intensity statin, % 1 | 30.1 | 30.9 | 28.1 | 24.8 | 27.3 | 28.5 |
| Monotherapy | 96.2 | 93.9 | 97.4 | 96.0 | 96.0 | 95.1 |
| Plus ezetimibe | 2.6 | 4.1 | 1.6 | 2.7 | 2.6 | 3.2 |
| Plus other nonstatin LLT | 1.2 | 2.0 | 1.0 | 1.4 | 1.4 | 1.6 |
| Low‐intensity statin, % 1 | 4.5 | 4.7 | 5.9 | 5.2 | 5.2 | 5.0 |
| Monotherapy | 97.7 | 96.2 | 98.3 | 97.5 | 97.4 | 97.0 |
| Plus ezetimibe | 1.5 | 2.1 | 0.7 | 1.3 | 1.2 | 1.5 |
| Plus other nonstatin LLT | 0.9 | 1.7 | 1.0 | 1.2 | 1.3 | 1.4 |
| Nonstatin LLT only, % 1 | 0.7 | 1.1 | 0.8 | 1.0 | 0.9 | 1.0 |
| Ezetimibe | 55.0 | 55.8 | 47.8 | 48.4 | 47.3 | 51.3 |
| Other nonstatin LLT | 45.0 | 44.2 | 52.2 | 51.6 | 52.7 | 48.7 |
| Not currently treated by LLT, % 1 | 37.8 | 46.9 | 55.8 | 62.6 | 59.2 | 54.1 |
| Previously on high‐intensity statin | 13.7 | 7.3 | 4.5 | 2.8 | 3.6 | 4.9 |
| Previously on medium‐intensity statin | 22.2 | 17.4 | 16.4 | 11.5 | 14.2 | 15.1 |
| Previously on low‐intensity statin | 4.1 | 3.7 | 4.3 | 3.0 | 3.6 | 3.6 |
| Previously on nonstatin LLT | 1.4 | 1.4 | 1.1 | 1.2 | 1.2 | 1.3 |
| No previous LLT | 58.6 | 70.1 | 73.8 | 81.4 | 77.4 | 75.0 |
Abbreviations: ACS, acute coronary syndrome; ASCVD, atherosclerotic cardiovascular disease; CHD, coronary heart disease; DM, diabetes mellitus; LLT, lipid‐lowering therapy; PAD, peripheral arterial disease.
1
Numbers in this row are absolute percentages and add up to 100% vertically. All other numbers are relative percentages of the absolute percentages.